Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now
Stake logo


Senseonics Holdings, Inc.

1 day chart

About SENS

Senseonics Holdings, Inc. is a medical technology company. The Company is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. It is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.

Buy US stocks in Australia starting with SENS. Open an account and start investing today!

Market Capitalisation


Price-earnings ratio


Dividend yield




High today


Low today


Open price


52-week high


52-week low


What does Senseonics do and how does it earn money?

It's in the blood. Senseonics Holdings, Inc. is a medical technology company that develops and manufactures Continuous Glucose Monitoring (CGM) systems, aiming “to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.” 

The company’s CGMs are an industry first. While others require weekly or fortnightly replacements, Senseonics’ CGMs can be implanted subcutaneously for much longer periods.

The company earns revenue in one business segment via three main products: 

  • Eversense CGM which can be implanted subcutaneously for 3 months 

  • Eversense XL CGM which can be implanted subcutaneously for 6 months (currently available in Europe only)

  • Eversense E3 CGM which can be implanted subcutaneously for 6 months

In August 2020, Senseonics entered a Commercialization Agreement with Ascensia, a global diabetes treatment company. Senseonics granted Ascensia exclusive rights to distribute their Eversense CGM systems worldwide.

How does Senseonics’ Eversense CGM work?

Senseonics’ CGM systems measure a diabetic’s glucose levels (aka blood sugar) via sensors inserted under the skin by a healthcare professional. 

The sensor communicates data to a smart transmitter on top of the skin. The transmitter beams data to a smartphone app for real-time diabetes monitoring and management.

Is Senseonics profitable?

No, Senseonics is not profitable at this time. 

By their own admission, the company is in “the early commercialization stages of the Eversense brand and are focused on driving awareness of our CGM systems amongst intensively managed patients and their healthcare providers.”

Revenue has see-sawed since the company went public and net income has always been negative. In fact, net income has trended deeper into the red in FY2019, FY2020 and FY2021 with minus US$116m, US$175m and US$302m, respectively.

As of the end of FY2021, the company has accumulated a total debt of US$62.7m.

Is SENS stock a buy?

Investor sentiment on SENS is mixed. Some investors consider Senseonics uninvestable due to its weak and inconsistent financials. 

Other investors anticipate a brighter future for the company due to the U.S. Food & Drug Administration’s (FDA) recent approval of the Eversense E3 CGM system in February 2022.

These investors are also anticipating widening adoption of Eversense CGMs due to the Commercialization Agreement with Ascensia.

Who owns SENS stock?

Senseonics largest shareholders are institutional including PHC Holdings Corporation (14.75%), BlackRock (6.71%), Vanguard Group (4.35%) and Steward Capital Holdings (4.1%).

President and CEO Timothy T. Goodnow holds 0.3%.


Yes, the Stake platform allows you to buy SENS shares and over 8,000 stocks and ETFs across the ASX and Wall St.

One share of Senseonics Holdings, Inc. is valued at $0.68.

The ticker symbol for Senseonics Holdings, Inc. is SENS.

To buy SENS stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in SENS

The Senseonics Holdings, Inc. 52-week high stock price is $1.12.

The Senseonics Holdings, Inc. 52-week low stock price is $0.46.

As of 20/02/2024 Senseonics Holdings, Inc. has a market cap of $382.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.